News Detail
Boston, 11 Dec 2024: A novel, fixed-duration drug combination — consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug — shows deep and durable responses in patients with ch......
View Details
Source : Dana-Farber Cancer Institute
Blood
Blood Cancer
Cancer
Children
Chronic
Chronic Lymphocytic Leukemia
Efficacy
Hematology
Hospital
Leukemia
Research
Rituximab
Related News
- UT man duped of Rs 1.4 lakh in fake Patanjali treatment scam (13-01-2025)
- Kidney, liver damage in 3 new moms given faulty drip (13-01-2025)
- WB govt bans 10 intravenous fluids in hospitals for patient safety (13-01-2025)
- 15 lakh annual surgical site infections in India:ICMR study (13-01-2025)
- NCB and police seized Narcotic capsules in Hindaun City, one arrested (12-01-2025)
- Assam: Massive consignment of illicit cough syrup seized in Guwahati (12-01-2025)
- Police probe company behind tramadol diversion in Punjab (12-01-2025)
- ACB caught UP Pharmacy Council contract worker red-handed accepting bribe of Rs 5,000 (12-01-2025)
- Medical shop running without license, medicines worth 50 thousand seized (12-01-2025)
- Drug business under the guise of medicine shop: 600 injections seized (12-01-2025)